Treatment Considerations in MDS from ASCO/EHA 2022
EHA 2022 Magrolimab in Combination With Azacitidine for Untreated Higher-Risk MDS: 5F9005 Phase 1b Study Results
By
EHA 2022 Conference Coverage
FEATURING
David Sallman
By
EHA 2022 Conference Coverage
FEATURING
David Sallman
Login to view comments.
Click here to Login
Treatment Considerations in MDS from ASCO/EHA 2022